Previous 10 | Next 10 |
Athersys Inc. (NASDAQ:ATHX) traded at a new 52-week high today of $4.49. This new high was reached on above average trading volume as 148.6 million shares traded hands, while the average 30-day volume is approximately 1.8 million shares. In the past 52 weeks, Athersys Inc. share prices a...
Development-stage biotech, Athersys (NASDAQ:ATHX) is trading ~11% lower in the pre-market on Monday after announcing that its partner, HEALIOS K.K., has delayed plans to seek regulatory approval for MultiStem cell therapy for acute respiratory distress syndrome (ARDS) in Japan. The ...
Last 365-day patient follow-up visit was completed on schedule for the Phase 2/3 TREASURE study for ischemic stroke Topline results expected to be announced in May Athersys, Inc. (Nasdaq: ATHX) announced today that its partner, HEALIOS K.K. (Heali...
Company presentations scheduled at the Locust Walk Stem Cell Conference, April 11, and at the Needham Healthcare Conference, April 13 Athersys, Inc. (Nasdaq: ATHX) announced today that William (B.J.) Lehmann, President and Chief Operating Officer, will present a corporate ov...
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q4 2021 Earnings Call Mar 15, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Athersys (ATHX) Q4 2021 Earnings Call Transcript
Athersys, Inc. (ATHX) Q4 2021 Results Conference Call March 15, 2022 4:30 PM ET Company Participants Karen Hunady - IR Daniel Camardo - CEO William Lehmann - President, COO Ivor Macleod - CFO Conference Call Participants David Hoang - SMBC Gil Blum - Needham & Co. Greg Harrison - BofA Glo...
Athersys press release (NASDAQ:ATHX): Q4 GAAP EPS of -$0.09. Revenue of $0.72M (-43.3% Y/Y). For further details see: Athersys GAAP EPS of -$0.09, revenue of $0.72M
Management to host conference call at 4:30 pm ET today; Dan Camardo, newly appointed Chief Executive Officer, will lead the call and share his initial perspective on the path to commercial success for the Company Athersys, Inc. (Nasdaq: ATHX) announced today ...
OTCPK:ANCUF, ATHX, CAL, CHMI, CLPR, FF, GOCO, HYRE, KODK, LFT, LOTZ, LX, MTN, OPNT, S, SFT, SMAR, SRG, SRGA, TCON, YALA, YY, ZDGE For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close
Athersys (NASDAQ:ATHX) is scheduled to announce FY earnings results on Tuesday, March 15th, after market close. The consensus EPS Estimate is -$0.08 (+27.3% Y/Y) and the consensus Revenue Estimate is $7.5M (+490.6% Y/Y). For further details see: Athersys FY 2021 Earnings Preview
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...